Correlation Engine 2.0
Clear Search sequence regions

  • chronic disease (1)
  • endothelin (16)
  • endothelin 1 (2)
  • ET 1 (2)
  • human (2)
  • men (1)
  • receptor (5)
  • renal disease (1)
  • sex differences (2)
  • sex hormones (1)
  • sexes (3)
  • sodium (1)
  • women (2)
  • Sizes of these terms reflect their relevance to your search.

    Hypertension and chronic kidney disease are more common in men than in premenopausal women at the same age. In animal models, females are relatively protected against genetic or pharmacological procedures that produce high blood pressure and renal injury. Overactivation or dysfunction of the endothelin (ET) system modulates the progression of hypertension or kidney diseases with the ET(A) receptor primarily mediating vasoconstriction, injury and anti-natriuresis, and ET(B) receptors having opposite effects. The purpose of this review is to examine the role of the ET system in the kidney with a focus on the inequality between the sexes associated with the susceptibility to and progression of hypertension and kidney diseases. In most animal models, males have higher renal ET-1 mRNA expression, greater ET(A) -mediated responses, including renal medullary vasoconstriction, and increased renal injury. These differences are reduced following gonadectomy suggesting a role for sex hormones, mainly testosterone. In contrast, females are relatively protected from high blood pressure and kidney damage via increased ET(B) versus ET(A) receptor function. Furthermore, ET(A) receptors may have a favourable effect on sodium excretion and reducing renal damage in females. In human studies, the genetic polymorphisms of the ET system are more associated with hypertension and renal injury in women. However, the knowledge of sex differences in the efficacy or adverse events of ET(A) antagonists in the treatment of hypertension and kidney disease is poorly described. Increased understanding how the ET system acts differently in the kidneys between sexes, especially with regard to receptor subtype function, could lead to better treatments for hypertension and renal disease. LINKED ARTICLES This article is part of a themed section on Endothelin. To view the other articles in this section visit © 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.


    W Kittikulsuth, J C Sullivan, D M Pollock. ET-1 actions in the kidney: evidence for sex differences. British journal of pharmacology. 2013 Jan;168(2):318-26

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 22372527

    View Full Text